Robert P. Mauch Sells 4,969 Shares of Cencora, Inc. (NYSE:COR) Stock

Cencora, Inc. (NYSE:COR) CEO Robert P. Mauch sold 4,969 shares of the company’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer now owns 47,582 shares of the company’s stock, valued at $13,766,900.06. This trade represents a 9.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Cencora Price Performance

COR opened at $286.08 on Wednesday. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The company’s 50-day moving average price is $265.58 and its 200 day moving average price is $248.02. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $296.65. The firm has a market cap of $55.48 billion, a price-to-earnings ratio of 40.69, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.77%. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on COR shares. Wells Fargo & Company upped their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research report on Friday, March 14th. Bank of America increased their price target on Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Friday, April 11th. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday, March 12th. JPMorgan Chase & Co. upped their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Finally, Evercore ISI raised their price target on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and a consensus price target of $284.55.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Hoey Investments Inc. acquired a new position in shares of Cencora during the first quarter worth approximately $28,000. JFS Wealth Advisors LLC increased its holdings in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after purchasing an additional 46 shares during the period. Banque Transatlantique SA bought a new stake in shares of Cencora during the fourth quarter valued at about $29,000. SBI Securities Co. Ltd. acquired a new stake in Cencora in the fourth quarter worth about $30,000. Finally, Kentucky Trust Co bought a new position in Cencora in the 4th quarter valued at about $33,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.